{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:47:56Z","timestamp":1760014076078,"version":"3.37.3"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"1134","license":[{"start":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T00:00:00Z","timestamp":1570579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001786","name":"The University of Adelaide","doi-asserted-by":"publisher","award":["Divisional Scholarship"],"award-info":[{"award-number":["Divisional Scholarship"]}],"id":[{"id":"10.13039\/501100001786","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001786","name":"The University of Adelaide","doi-asserted-by":"crossref","award":["Divisional Scholarship"],"award-info":[{"award-number":["Divisional Scholarship"]}],"id":[{"id":"10.13039\/501100001786","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose of the study<\/jats:title><jats:p>This study investigates spontaneous adverse drug reactions (ADRs) to glucosamine and chondroitin in the Australian population between 2000 and 2011, with a primary focus on hypersensitivity reactions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Study design<\/jats:title><jats:p>Case reports of ADR to glucosamine and chondroitin sent to the Therapeutic Goods Administration between 2000 and 2011 were obtained and analysed. The demographic information and severity of the ADR were recorded for individual ADR cases. These reactions were classified according to the Brown et al grading system for generalised hypersensitivity reactions. This included mild hypersensitivity reactions (generalised erythema, urticaria and angioedema) through to moderate hypersensitivity reactions (wheeze, nausea, vomiting, dizziness (presyncope), diaphoresis, chest or throat tightness and abdominal pain), and more severe reactions (hypotension, confusion and collapse).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In this study of 366 ADRs to glucosamine and chondroitin preparations, 71.85% of cases (n=263) were found to have hypersensitivity reactions. Of these 263 cases, 92 cases were classified as mild (eg, pruritus, urticaria and lip oedema), 128 cases classified as moderate (such as dyspnoea, nausea and abdominal pain), and 43 cases classified as severe (including amnesia, gait disturbance, somnolence and hypotension). It is not clear whether the patients involved had a known shellfish allergy or underlying atopy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Results of this investigation support the need for clear labelling on glucosamine and chondroitin preparations to raise awareness of possible adverse events for those predisposed to allergy or atopy in response to shellfish.<\/jats:p><\/jats:sec>","DOI":"10.1136\/postgradmedj-2019-136957","type":"journal-article","created":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T21:15:36Z","timestamp":1570655736000},"page":"190-193","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Hypersensitive adverse drug reactions to glucosamine and chondroitin preparations in Australia between 2000 and 2011"],"prefix":"10.1093","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7027-5558","authenticated-orcid":false,"given":"Claire","family":"Hoban","sequence":"first","affiliation":[{"name":"Pharmacology, The University of Adelaide , Adelaide, South Australia , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Byard","sequence":"additional","affiliation":[{"name":"Anatomy and Pathology, The University of Adelaide , Adelaide, South Australia , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Musgrave","sequence":"additional","affiliation":[{"name":"Pharmacology, The University of Adelaide , Adelaide, South Australia , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,10,9]]},"reference":[{"key":"2023041707415380000_","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/ar3657","article-title":"Is there any scientific evidence for the use of glucosamine in the management of human osteoarthritis?","volume":"14","author":"Henrotin","year":"2012","journal-title":"Arthritis Res Ther"},{"article-title":"Australian register of therapeutic goods public summary of glucosamine 500mg tablets","year":"2008","author":"Therapeutic Goods Administration","key":"2023041707415380000_"},{"key":"2023041707415380000_","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3109\/s10165-006-0490-6","article-title":"Cartilage destruction by matrix degradation products","volume":"16","author":"Yasuda","year":"2006","journal-title":"Mod Rheumatol"},{"key":"2023041707415380000_","doi-asserted-by":"crossref","DOI":"10.1186\/s40001-015-0176-7","article-title":"Beneficial reward-to-risk action of glucosamine during pathogenesis of osteoarthritis","volume":"20","author":"Kang","year":"2015","journal-title":"Eur J Med Res"},{"key":"2023041707415380000_","first-page":"853","article-title":"Management of the osteoarthritic knee. New advances in nonoperative therapy","volume":"30","author":"Vertullo","year":"2001","journal-title":"Aust Fam Physician"},{"key":"2023041707415380000_","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s10719-016-9665-3","article-title":"Chondroitin sulphate: a focus on osteoarthritis","volume":"33","author":"Bishnoi","year":"2016","journal-title":"Glycoconj J"},{"key":"2023041707415380000_","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jaci.2004.05.050","article-title":"Is glucosamine safe in patients with seafood allergy?","volume":"114","author":"Gray","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"2023041707415380000_","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0140-6736(14)60802-3","article-title":"Osteoarthritis","volume":"386","author":"Glyn-Jones","year":"2015","journal-title":"Lancet"},{"key":"2023041707415380000_","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.joca.2014.01.003","article-title":"OARSI guidelines for the non-surgical management of knee osteoarthritis","volume":"22","author":"McAlindon","year":"2014","journal-title":"Osteoarthritis Cartilage"},{"key":"2023041707415380000_","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s12016-014-8429-8","article-title":"Shellfish allergy: a comprehensive review","volume":"49","author":"Pedrosa","year":"2015","journal-title":"Clin Rev Allergy Immunol"},{"key":"2023041707415380000_","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1034\/j.1398-9995.1999.00925.x","article-title":"Pattern of food-induced anaphylaxis in children of an Asian community","volume":"54","author":"Goh","year":"1999","journal-title":"Allergy"},{"key":"2023041707415380000_","doi-asserted-by":"crossref","DOI":"10.1007\/s11882-016-0601-1","article-title":"Classification of food allergens and cross-reactivity","volume":"16","author":"Kazatsky","year":"2016","journal-title":"Curr Allergy Asthma Rep"},{"article-title":"Allergic and toxic reactions to seafood","year":"2014","author":"Australasian Society of Clinical Immunology and Allergy (ASCIA)","key":"2023041707415380000_"},{"key":"2023041707415380000_","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/1440-1681.12424","article-title":"A comparison of patterns of spontaneous adverse drug reaction reporting with St. John\u2019s wort and fluoxetine during the period 2000-2013","volume":"42","author":"Hoban","year":"2015","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2023041707415380000_","first-page":"30054","article-title":"Analysis of spontaneous adverse drug reactions to Echinacea, valerian, black cohosh and Ginkgo in Australia from 2000 to 2015","author":"Hoban","year":"2019","journal-title":"J Integr Med"},{"key":"2023041707415380000_","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jaci.2004.04.029","article-title":"Clinical features and severity grading of anaphylaxis","volume":"114","author":"Brown","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"2023041707415380000_","first-page":"3","article-title":"Shellfish allergy-an Asia-Pacific perspective","volume":"30","author":"Lee","year":"2012","journal-title":"Asian Pac J Allergy Immunol"},{"key":"2023041707415380000_","first-page":"37","article-title":"Food allergy in Alergol\u00f3gica\u20142005","volume":"2009","author":"Fern\u00e1ndez-Rivas","year":"2009","journal-title":"J Investig Allergol Clin Immunol"},{"key":"2023041707415380000_","first-page":"481","article-title":"Asthma exacerbation associated with glucosamine-chondroitin supplement","volume":"15","author":"Tallia","year":"2002","journal-title":"J Am Board Fam Pract"},{"key":"2023041707415380000_","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1080\/08820139.2016.1180301","article-title":"Seafood-associated shellfish allergy: a comprehensive review","volume":"45","author":"Khora","year":"2016","journal-title":"Immunol Invest"},{"key":"2023041707415380000_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2045-7022-1-3","article-title":"Not all shellfish \"allergy\" is allergy!","volume":"1","author":"Woo","year":"2011","journal-title":"Clin Transl Allergy"},{"key":"2023041707415380000_","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.anai.2017.05.014","article-title":"Adult-Onset food allergies","volume":"119","author":"Ramesh","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2023041707415380000_","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/dmrr.1150","article-title":"A comprehensive review of oral glucosamine use and effects on glucose metabolism in normal and diabetic individuals","volume":"27","author":"Simon","year":"2011","journal-title":"Diabetes Metab Res Rev"},{"article-title":"Australia\u2019s medicine labels are becoming clearer","year":"2017","author":"Therapeutic Goods Administration","key":"2023041707415380000_"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/96\/1134\/190\/49933418\/postgradmedj-96-190.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/96\/1134\/190\/49933418\/postgradmedj-96-190.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T12:32:40Z","timestamp":1695299560000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/96\/1134\/190\/6842838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,9]]},"references-count":24,"journal-issue":{"issue":"1134","published-online":{"date-parts":[[2019,10,9]]},"published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.1136\/postgradmedj-2019-136957","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"type":"print","value":"0032-5473"},{"type":"electronic","value":"1469-0756"}],"subject":[],"published-other":{"date-parts":[[2020,4]]},"published":{"date-parts":[[2019,10,9]]}}}